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Abstract
Background: Patched 1 (Ptc1) is a polytopic receptor protein that is essential for growth and differentiation. Its extracellular
domains accept its ligand, Sonic Hedgehog, while the function of its C-terminal intracellular domain is largely obscure.
Principal Findings: In this study, we stably expressed human Ptc1 protein in HeLa cells and found that it is subjected to
proteolytic cleavage at the C-terminus, resulting in the generation of soluble C-terminal fragments. These fragments
accumulated in the nucleus, while the N-terminal region of Ptc1 remained in the cytoplasmic membrane fractions. Using an
anti-Ptc1 C-terminal domain antibody, we provide conclusive evidence that C-terminal fragments of endogenous Ptc1
accumulate in the nucleus of C3H10T1/2 cells. Similar nuclear accumulation of endogenous C-terminal fragments was
observed not only in C3H10T1/2 cells but also in mouse embryonic primary cells. Importantly, the C-terminal fragments of
Ptc1 modulate transcriptional activity of Gli1.
Conclusions: Although Ptc1 protein was originally thought to be restricted to cell membrane fractions, our findings suggest
that its C-terminal fragments can function as an alternative signal transducer that is directly transported to the cell nucleus.
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Introduction
Patched 1 (Ptc1) is a polytopic membrane protein that is an
essential component of the receptor for Hedgehog (Hh) signaling
[1–5]. The Ptc1 signaling pathway regulates a range of processes
involved in developmental differentiation, stem cell growth, and
cancer etiology [4–9]. Malfunction of Ptc1 in mice leads to
embryonic lethality, indicating that it is an essential protein in the
early development of mammals [10]. In humans, ptc1 acts as a
tumor suppressor gene, as shown by the presence of inactivating
mutations in a ptc1 that occur in sporadic and inherited forms of
the common skin tumor, basal cell carcinoma (BCC) [11–13], and
brain tumors [14,15]. Thus, it is clear that Ptc1 is crucial for
growth and differentiation in vertebrates. Despite its biological
importance, the intracellular signaling pathway of mammalian
Ptc1 still remains largely elusive.
The downstream pathway of Sonic Hedgehog (Shh) and Ptc1
involves two key proteins, the oncogenic transcription factor Gli
and the trans-membrane protein smoothened (Smo) [5,16,17]. In
the absence of Shh, Ptc1 represses Gli-dependent transcription
through Smo inhibition [2,18]. Extracellular domains of Ptc1 are
essential for accepting its ligand, Shh, and binding of Shh alleviates
Smo repression, causing activation of Gli1-dependent transcrip-
tion. In contrast to the understanding of extracellular domain
functions, the role of the intracellular domain (ICD) of Ptc1 is
rather obscure. Several previous studies imply that the C-terminal
end of Ptc1, the seventh and largest intracellular domain
(designated Ptc-ICD7 hereafter), is also functional. Ptc-ICD7 was
required for appropriate regulation of the Hh signaling pathway in
Drosophila [19,20], and deletion of the C-terminal 156 residues of
Drosophila Ptc was shown to compromise Hh target gene repression
[19]. A spontaneous mouse mutant encoding a C-terminally
truncated Ptc1 protein [21,22] showed defects in A-P polarity of
the limb bud, and demonstrated increased expression of Shh target
genes in white fat tissue [22]. Furthermore, polymorphic variation
of Ptc-ICD7 at T1267 was shown to be essential for susceptibility
to H-ras-induced squamous carcinoma [23]. In humans, it was
revealed that several oncogenic mutations of Ptc1 map to positions
corresponding to the ICD7 region [11,24–26]. These findings
highlight the functional importance of Ptc-ICD7 in the Hh-
mediated signal transduction pathway, though the exact mecha-
nism of Ptc-ICD7 remains unclear.
In Caenorhabditis elegans, the transcriptional activity of TRA-1, a
single homolog of the mammalian Gli transcriptional factor, is
regulated by the tra-2 gene product [27–29] and, indeed, TRA-2
and human Ptc1 share several similar characteristics. They are
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with TM domains arranged in two sets of (1+3+2) membrane-
spanning domains reminiscent of some RND-family transporters
[17]. TRA-2 is a receptor for secreted glycoprotein HER-1 and
modulates the transcriptional activity of TRA-1. The largest
seventh intracellular domain of TRA-2 (designated TRA-2 ICD7
hereafter) is located at the C-terminus (Figure S1A, B).
Interestingly, several studies indicate that TRA-2 ICD7 has its
own biological activity. First, an alternative spliced transcript of
tra-2, named tra-2b, was identified in germline cells of hermaph-
rodites, and shown to encode a TRA-2 ICD7 fragment [30].
Second, Lum et al. (2000) reported that forced expression of
exogenous tra-2b results in the predominant localization of TRA-2
ICD7 fragment in the nuclei of somatic cells, and causing
complete somatic feminization of XO animals [31]. This indicates
that TRA-2 ICD7 fragment has transcriptional regulatory activity
in the nucleus. Third, Kuwabara and co-workers demonstrated
that proteolytic cleavage by calpain-like protease TRA-3 generates
a soluble ICD7 fragment from the membrane-bound form of
TRA-2 [32]. Furthermore, we previously found that the
endogenous TRA-2 ICD7 fragment accumulates in the nucleus
where it stimulates female-specific transcription in hermaphrodites
[33]. These observations indicate that the generation and
translocation of the TRA-2 ICD7 fragment into the nucleus is a
biologically relevant event in transcriptional regulations in the case
of nematodes.
In this study, we found that forced expression of TRA-2 ICD7
fragment in mammalian cells resulted in its clear nuclear
accumulation. Stimulated with this observation, we paid our
attention to the case in mammalian Ptc1. We found that human
Ptc1 protein that was stably expressed in HeLa cells was subjected
to proteolytic cleavage at its C-terminus, resulting in the
generation of soluble ICD7 fragments. We subsequently observed
accumulation of Ptc-ICD7 fragments in the nucleus, while the N-
terminal region of Ptc1 remained in the membrane vesicle.
Furthermore, we provide conclusive evidence that C-terminal
fragments of endogenous Ptc1 accumulate in the nucleus in a wide
variety of mammalian cells. Importantly, the ICD7 fragments of
human Ptc1 modulate transcriptional activity of Gli1. From these
observations, we suggest the existence of a novel alternative
signaling pathway for mammalian Ptc1 that is mediated by the
generation and nuclear translocation of ICD7 fragments.
Results
C-terminal fragments of nematode TRA-2 and human
Ptc1 have a potential to localize in the nucleus of human
cells
As we reported previously, endogenous fragments of TRA-2
ICD7 accumulate in the nucleus of C. elegans hermaphrodite
intestinal cells (Figure S2A) [33]. In good agreement with this
result, Lum et al. reported that GFP-tagged TRA-2 ICD7
fragment, overproduced from the heat shock promoter, localized
predominantly to nuclei of nematode somatic cells [31]. In the
present study, we show that forced expression of the FLAG-tagged
TRA-2 ICD7 fragment in human HeLa cells resulted in clear
nuclear localization (Figure S2B). These results potentially indicate
that the mechanisms for nuclear translocalization of ICD7 are
conserved between nematodes and human.
As shown in Figure S1C, ICD7 regions of human Ptc1 and
nematode TRA-2 share moderate amino acid sequence similarity
(29% identity and 55% similarity). We therefore investigated
possible nuclear localization of human Ptc-ICD7 fragments.
Forced expression of the C-terminally-FLAG-tagged Ptc-ICD7
fragment in HeLa cells resulted in aggregation in the cytoplasm
and the fragment fail to accumulate in the nucleus (Figure 1A, B).
However, we found that reduction of the Ptc-ICD7 synthesis rate
by the addition of the protein synthesis inhibitor cyclohexamide (at
0.4 mg/mL) clearly induced the nuclear translocation of the Ptc-
ICD7 fragment (Figure 1C, D). Immunosignals in the nucleus
appear to be specific to the ectopically-expressed FLAG-tagged
Ptc-ICD7 fragment, since the addition of higher concentrations of
cyclohexamide (12.5 mg/mL, Figure 1E, F) or mock transfection
(Figure 1G, H) completely abolished nuclear staining. Western
blot quantification indicates that treatment with 0.4 mg/mL
cyclohexamide reduced the expression of FLAG-tagged Ptc-
ICD7 to less than half of that of ‘‘No cyclohexamide’’ control
(Figure 1I). These observations indicate that a moderate rate of
Ptc-ICD7 production in cells is essential for its nuclear
translocation.
Stable introduction of full-length Ptc1 gene into the HeLa
cell genome leads to the spontaneous generation of
ICD7 fragments
Ptc1 is a twelve-passed trans-membrane protein that is rich in
hydrophobic amino acids (Figure S1A, B), so its forced expression
in HeLa cells tends to result in cytoplasmic aggregation. To
prevent this, we established HeLa cell lines stably transfected with
a cDNA fragment encoding human full-length Ptc1 (isoform L). As
shown in Figure S3, the expression level of ectopic Ptc1 protein in
a stable cell line is less than one fifth of that of transient over-
expression. In the stably transfected cell line we used, full-length
Ptc1 was fused with an N-terminal 36T7-tag and C-terminal
36FLAG-tag (Figure 2A), to distinguish the behavior of either half
of this trans-membrane protein. We then performed immunoblot
experiments to verify its expression. After immunoprecipitation
with anti-FLAG antibody, the N-terminal T7-tag blot clearly
showed expression of the 140 kDa full-length form of Ptc1
(Figure 2B, left panel). It should be noted, however, that the C-
terminal anti-FLAG-tag blot detected several small species of
molecular weights 25–36 kDa, which are likely to correspond to
fragments encompassing the intracellular domain of Ptc1, in
addition to the expected 140 kDa full-length form of the receptor
(Figure 2B, right panel). Unexpectedly, we noticed that pretreat-
ment of cells with 10 mM protease inhibitor MG132 modulated
the band pattern of smaller species (Figure 2B, right panel). To
further investigate the effects of inhibitors, we examined the
behavior of the C-terminal band pattern with a series of protease
inhibitors. Our analysis showed that neither calpain nor c-
secretase inhibitors had obvious effects on the processing of Ptc-
ICD7 (Figure S5). We found that treatment with Lactacystin, as
well as MG132, modulated the appearance of smaller species
(Figure S5). Since both Lactacystin and MG132 are known as
proteasome inhibitors, these observations indicate that proteolytic
cleavage of the C-terminal cytoplasmic domain of stably expressed
human Ptc1 is modulated by proteasome, either directly or
indirectly, resulting in the formation of soluble Ptc-ICD7
fragments. The precise mechanism of proteolytic cleavage control
is, however, currently unknown.
Subcellular localization of stably expressed human Ptc1
To analyze the subcellular localization of stably expressed
human Ptc1, we stained stably transfected cells with anti-N-
terminal T7 tag and/or anti-C-terminal FLAG-tag antibodies.
With the anti-N-terminal T7-tag antibody, the large cytoplasmic
punctuates observed (Figure 2C-a). This localization pattern is
consistent with the previously reported cellular localization of
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bodies and endosomes, likely representing transit through the
secretory and/or endocytic pathways.
By contrast, C-terminal staining with the anti-FLAG-tag
antibody was mostly in the nucleus (Figure 2C-b, c), suggesting
that they can be cleaved off and transported here. To verify this,
we analyzed the distribution of Ptc-ICD7 fragments using cell
fractionation method. As shown in Figure 2D, full-length Ptc1 was
detectable in both the cytoplasmic and nuclear membrane fraction
of HeLa cells, supporting previous observations that most full-
length Ptc1 is localized on cytoplasmic membrane fractions. In
contrast, the 25–36 kDa C-terminal ICD7 fragments were
specifically present in the nuclear fraction (Figure 2D, upper
panel). As described previously, pretreatment of cells with MG132
also modulated the band pattern of these nuclear fragments
(Figure 2D). Both of these biochemical and immunocytochemical
observations indicate that C-terminal fragments of Ptc1 (detected
by the antibody against C-terminal FLAG tag) are processed by
unidentified endoproteinase and the ICD7 fragments are specif-
ically translocated to the nucleus.
Establishment of a specific antibody for the C-terminus of
Ptc1
The cellular behavior of endogenous Ptc-ICD7 fragments in
mammalian cells is enigmatic as an appropriate C-terminal-
specific antibody had not been available. We therefore newly
established a polyclonal antibody to a synthetic peptide (1420-
CERRDSKVEVIELQD-1434) that is derived from the C-
terminal sequence of human Ptc-ICD7 (Figure 3A, B). It should
be noted that the antigenic sequence is completely conserved
between human and mouse (Figure 3B), thus it can be applicable
for both of these species. We designate this newly established
polyclonal IgG as anti-Ptc-ICD7 (1420–1434) antibody. This
antibody recognized both full-length and C-terminal fragments of
mammalian Ptc1 that was overexpressed in HeLa cells (Figure S4).
We next examined endogenous Ptc1 protein in C3H10T1/2
cells, mouse embryonic fibroblast cells that have the potential to
undergo osteoblast differentiation in response to Shh [37–40],
indicating that the Ptc1-dependent signaling pathway is active in
this cell line. We verified the expression of endogenous Ptc1
protein in this cell line with a commercially available antibody.
Western blot analysis of C3H10T1/2 cell lysates with an anti-
Ptc1-SSD antibody that recognizes the sterol-sensing domain
(SSD, residues 500–600 of human Ptc1, Figure 3A) of mammalian
Ptc1 reacted with signal correspond to membrane-assembled form
of Ptc1 (Figure 3C, right lane, indicated by an arrow). In identical
conditions, we found that our anti-Ptc-ICD7 (1420–1434)
antibody detected a 37-kDa signal that might correspond to the
endogenous ICD7 fragment of mouse Ptc1 (Figure 3C, left lane,
indicated by an arrowhead). This signal was completely absorbed
by the addition of excess peptide corresponding to the antigen,
indicating that the signal is specific (Figure 3C, central lane). For
Figure 1. Modest expression of Ptc-ICD7 fragment leads to its nuclear accumulation. C-terminally-FLAG-tagged Ptc-ICD7 cDNA in pCI-neo
expression vector was transfected into HeLa cells (Ptc-ICD7-FLAG TF) and immunostained with anti-FLAG antibody. At the time of cDNA transfection,
protein synthesis inhibitor cyclohexamide (CHX) was added at indicated concentrations. ‘‘No CHX’’ indicates cell culture without CHX addition (A, B).
Cells were harvested 24 hr after transfections. Addition of 12.5 mg/mL CHX completely suppressed protein expression from transfected expression
plasmid (E, I), while the addition of 0.4 mg/mL CHX reduced expression of FLAG-tagged Ptc-ICD7 to less than half compared with ‘‘No CHX’’ (I). ‘‘Mock-
TF’’ indicates empty vector transfection without CHX addition as a negative control (G, H). Anti-FLAG immunostain in green (A, C, E, G), and DAPI DNA
stain in blue (B, D, F, H). Scale bar, 20 mm.
doi:10.1371/journal.pone.0018638.g001
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that correspond to the full-length form of mouse Ptc1 in
C3H10T1/2 cells with anti-Ptc-ICD7 (1420–1434) antibody.
Endogenous Ptc-ICD7 fragments can be detected in the
nucleoplasm of mammalian cells
We next examined the subcellular localization of endogenous Ptc1
p r o t e i ni nC 3 H 1 0 T 1 / 2c e l l s .I m m u n o c y t o c h e m i c a ls t a i n i n go f
C3H10T1/2 cells with antibody that specifically recognizes the
SSD domain showed punctate cytoplasmic staining that would be
expected for intracellular endocytic membrane vesicles (Figure 4C,
D).Thesepatterns are consistent with the previously reported cellular
localizationoffull-lengthPtc1 [34–36]. By contrast, immunosignalsof
the anti-Ptc-ICD7 (1420–1434) antibody at a final concentration of
5.5 nM showed clear nuclear staining (Figure 4 A, B), suggesting that
endogenous fragments of Ptc-ICD7 can be transported into the
nucleus. We also provide evidence that C-terminal fragments from
endogenous Ptc1 accumulate not only in the nuclei of C3H10T1/2
cultured cell line but also in that of mouse primary cells from 14 dpc
embryos (Figure 5A, B). These observations indicating that the
nuclear localization of Ptc-ICD7 could be a general event, although
strength of nuclear signals was varied from cell to cell in the case of
mouse primary cells. These nuclear staining were specific to Ptc1
protein, as immunostaining with non-immune control IgG (Figure 4,
K, L, Figure 5, E, F) and anti-a-tubulin antibody (Figure 4, E, F,
Figure 5, C, D) showed no nuclear staining under identical
experimental conditions as those used in anti-Ptc-ICD7 (1420–
1434) antibody staining. To further evaluate antibody specificity for
nuclear staining, we performed an antigen competition assay. By
absorption using excess amounts of antigenic peptide (at a final
concentration of 1.2 mM peptide),we confirmed that immuno-signals
of the anti-Ptc-ICD7 (1420–1434) antibody (at a final concentration
of 5.5 nM IgG) in the nucleus of C3H10T1/2 cells were completely
abolished (Figure 4 I–J). Similarly, nuclear immunosignals in
embryonic primary cells were abolished with the 0.6 mMa n t i g e n i c
peptide competition (Figure 5 I–J).
Nuclear-specific accumulation of the endogenous Ptc-ICD7
fragment in C3H10T1/2 cells was further confirmed by a cell
fractionation assay. As shown in Figure 3D, C-terminal fragments
detected with the anti-Ptc-ICD7 (1420–1434) antibody were
specifically present in the nuclear fraction. Again, the immuno-
signal of 37 kDa in the nuclear fraction is specific since antigenic
peptide competition completely abolished the reactivity
(Figure 3D). Together, these results indicate that the anti-Ptc-
Figure 2. Subcellular localization of stably expressed Ptc1. (A) Schematic representation of stably transfected full-length human Ptc1 protein
with possess 12 transmembrane domains. Red box at N-terminus indicates 36T7-tag, green box at end of intracellular domain indicates C-terminal
36FLAG-tag, respectively. (B) Western blot analyses of Ptc1 protein stably expressed in HeLa cells. Ptc1 immunoprecipitated from cell extracts with C-
terminal FLAG-tag and immunoblotted with anti-N-terminal T7 tag antibody (left panel) or anti-C-terminal FLAG tag antibody (right panel). Anti-T7
blot detects doublet bands corresponding to full-length Ptc1 (Ptc1 FL), while anti-FLAG blot reveals small C-terminal fragments representing the
intracellular domain of Ptc1 (ICD7 fragments) as well as Ptc1 FL. (C) Multiple staining of Ptc1-stably expressing cells by anti-T7 tag immunostain (a:
Ptc1 N-terminus), anti-FLAG-tag immunostain (b: Ptc1 C-terminus), DAPI DNA stain (c: nucleus) and their merged image (d). Scale bar, 20 mm. (D) Cell
fractionation analysis of Ptc1-stably expressing cells. BIP and Histone H2B used as cytoplasmic and nuclear marker, respectively. Ptc1 FL (+), cells
stably expressing full-length Ptc1; Ptc1 FL (2), control HeLa cells.
doi:10.1371/journal.pone.0018638.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18638Figure 3. Endogenous Ptc1 ICD7 fragment in C3H10T1/2 cell. (A) Schematic diagram of human Ptc1 protein (isoform L). Twelve
transmembrane (TM) domains are indicated by black boxes. Antigenic regions of SSD (500–600) and ICD7 (1420–1434) are indicated by underlines. (B)
Amino acid alignment of the C-terminus of Ptc1. Antigenic sequence of anti-Ptc-ICD7 (1420–1434) antibody is indicated by a box. Identical residues in
humans and mice are indicated by dots. (C) Western blot analysis with mouse C3H10T1/2 total cell lysate. Endogenous Ptc1 protein in cells was
detected with either anti-Ptc-ICD7 (1420–1434) antibody or anti-Ptc SSD (500–600) antibody. Inclusion of competitive antigenic peptide is indicated
as (2)o r( +). Asterisk indicates unidentified signal. (D) Cell fractionation assay of C3H10T1/2 cells. Each fraction was subjected to immunoblot analysis
using anti-Ptc-ICD7 (1420–1434) antibody. TCL: total cell lysate. Cyto.: cytoplasmic fraction. Nuc.: nuclear fraction. Antigenic peptide competition
abolished the 37 kDa immunosignal in the nuclear fraction.
doi:10.1371/journal.pone.0018638.g003
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nized corresponding target fragments in the nucleus. We therefore
suggest a novel signaling mechanism for mammalian Ptc1 that is
mediated by the generation and nuclear translocation of C-
terminal ICD7 fragments.
ICD7 fragments of Ptc1 modulates transcriptional activity
of Gli1
Itwasreported thatPtc1isessentialforcontrolling transcriptional
activity of Gli1 in Shh-dependent signaling pathway [16,17]. To
examine the effects of Shh-Ptc1 pathway on the Gli1 activity in our
experimental system, we performed a dual-luciferase-reporter assay
with a reporter construct consisting of eight copies of a Gli-binding
site (Gli-BS) present in the mouse HNF-3b enhancer [38,41]. To
determine the response specificity, we also used a reporter plasmid
carrying a mutated version of the Gli-binding site (mGli-BS) that is
unable to bind Gli1 [41]. Strong induction of luciferase was
observed when the Gli-BS reporter was co-transfected with a Gli1
expression plasmid, whereas the mGli-BS reporter resulted in
background levels of induction (Figure 6A). In this system, Gli1
activity was suppressed to less than 60% in cells stably expressing
full-length Ptc1 in comparison with Mock-transfected HeLa cells
(Figure 6A). It should be noted that the addition of a Shh-N (19 kDa
form of secreted Shh-N fragment) on cells stably expressing full-
length Ptc1 significantly activated the Gli1 (Figure 6A). This
observation supports the notion that the stably expressed Ptc1
protein in our system is assembled properly as a functional Shh-
receptor. In accordance with this view, we also confirmed that N-
terminally-T7-tagged human Ptc1 in stable cells co-precipitated
with Myc-tagged-Shh-N that was added in the media (Figure 6B).
Next, in an effort to determine the effect of Shh-N on the
production of Ptc1 ICD7, Ptc1-stably-transfected cells were
exposed to Shh-N-conditioned media. As shown in Figure 6C,
exposure to the Shh-N fragment caused an increase in the
production of ICD7 fragments. To address the biological activity
of Ptc-ICD7 fragment, we examined the effect of Ptc-ICD7
expression on Gli1 transcriptional activity. We found that forced
expression of Ptc-ICD7 fragment partly suppressed transcriptional
activity of Gli1 (Figure 6D). Although the biological relevance of
the Ptc-ICD7 fragment in the nucleus is still not conclusive, these
observations indicate that Ptc-ICD7 fragments themselves possess
some regulatory roles in the Gli1 activity.
Discussion
In this study, we have established a cell line stably expressing full-
length Ptc1 with N-terminal- and C-terminal-specific tags. Ptc1
protein thus synthesized in our stable cells could be properly
assembled since Shh-N in the media was co-immunoprecipitated
with Ptc1 from the solubilized extracts of these cells (Figure 6B). In
addition, these cells respond to the addition of Shh-N (Figure 6A,
C). With these cell lines, we found that the C-terminal cytoplasmic
domain of human Ptc1 is subjected to cleavage, resulting in the
generation of soluble ICD7 fragments. Importantly, we observed
that the accumulation of Ptc-ICD7 fragments in the nucleus, while
the N-terminal region of Ptc1 remained on the membrane fractions.
Identical nuclear targeting of endogenous Ptc-ICD7 fragments was
Figure 4. Nuclear localization of endogenous Ptc1 ICD7 fragments in C3H10T1/2 cells. Immunocytochemical analyses of endogenous Ptc1
protein in mouse C3H10T1/2 cells with a series of anti-Ptc1 antibody. Antibodies used are as follows: anti- Ptc-ICD7 (1420–1434) antibody (A), anti-
Ptc1 antibody that recognizes SSD (500–600) region (C). Anti-a-tubulin DM1A antibody used as positive control for cytoplasmic immunostaining (E),
and ‘‘Pre-immune serum’’ staining used as negative control (K). (G–J) Nuclear immunosignals of endogenous ICD7 fragments were competitively
suppressed by corresponding antigenic peptide. 5.5 nM anti-Ptc-ICD7 (1420–1434) primary antibody was absorbed with (I) or without (G) excessive
amounts of antigenic peptide. Antigenic peptide concentrations for competition were 1.2 mM. Hoechst DNA stain, blue (B, D, F, H, J, L). Scale bar,
20 mm.
doi:10.1371/journal.pone.0018638.g004
Nuclear Accumulation of Ptc1 C-Terminal Fragment
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18638also observed with its specific antibody. These results provide the
first evidence of nuclear localization of fragments derived from the
intracellular domain of mammalian Ptc1. Based on these observa-
tions, we would like to propose a novel signaling pathway for
mammalian Ptc1 that is mediated through the generation and
nuclear translocation of ICD7 fragments.
In the classical understanding of the patched-dependent signaling
pathway, the principal activity associated with Ptc1 is repression of
the activity of Smo, a G-protein coupled membrane protein
[5,6,16–18,42]. The downstream target of Smo is cytoplasmic
protein Suppressor of Fused (SuFu), and activation of Smo results in
rapid dissociation of the SuFu-Gli complex [43]. Thus, upon
binding of the Shh-ligand to Ptc1, inhibition of Smo is relieved,
allowing Gli to enter the nucleus and ultimately driving expression
of Hh-target genes. It has been suggested, however, that Ptc1 loss-
of-function is not functionally equivalent to Smo activation in
mammary epithelium, implying that Ptc1 might have Smo-
independent functions in the gland [44,45]. Indeed, it was proposed
that canonical and non-canonical pathways are likely to act in
parallel, as signaling that involves Hh pathway components but
which is independent of Smo-mediated regulation has been
reported [46–49]. It was also recently demonstrated that Ptc1 can
stimulate ERK1/2 phosphorylation upon stimulation by Shh in the
absence of Smo activity, suggesting that the Hh-signaling pathway
may have acquired additional characteristics in vertebrates where
direct regulation of intracellular signaling arises [49].
Although the canonical view contemplates Ptc1 protein restricted
to membrane fractions, our current findings suggest that it can
function as a novel signal transducers that is directly transported to
the cell nucleus where it probably modulates nuclear function. The
nuclear transport of cytoplasmic fragments generated from
transmembrane proteins is an important mechanism of transducing
signals directly from the plasma membrane to the nucleus [50,51].
For example, Ni et al. reported that c-secretase cleaved the C-
terminal region of ErbB4 receptor protein, which was then
translocated into the nucleus [52]. c-secretase also cleaves the
intracellular domain of Notch, generating a nuclear transcriptional
regulator NICD fragment [53]. In the case of Ptc1, the C-terminal
intracellular domain is similarly proteolyzed and moved into the
nucleus, although our preliminary analysis indicates that c-secretase
would not be responsible for the production of C-terminal
fragments (Figure S5). Identification of processing enzyme(s) as well
as determination of the precise processing site(s) within Ptc-ICD7
would be necessary for future study.
Although homozygotes of ptc1 null-knockout mice die around
E9.5 with severe neural tube defects [10], an interesting viable
mutant in the ptc1 allele, named mesenchymal dysplasia (mes) has been
reported [21,54]. Ptc1 mes encodes a mutant Ptc1 protein lacking
most of the C-terminal cytoplasmic domain [22]. mes homozygote
mice show no gloss defects in the developing spinal cord but exhibit
sterility in both sexes, and increased expression of Shh target genes
(Gli1, Gli2, Ptc2 and Ptc1) in white fat tissue [55]. Importantly, the
ptc
mes allele is haploinsufficient over the null allele. Indeed,
compound heterozygotes of ptc- and mes alleles (ptc
2/ptc
mes), which
die neonatally, show a malformation of the lung, which is more
severe than the viable phenotype of mes homozygotes [22].
Furthermore, ptc
2/ptc
mes mutant embryos showed preaxial poly-
dactyly in all four feet with perfect penetrance. These reports also
suggest that the C-terminal cytoplasmic domain of Ptc1 plays an
indispensable role in mice development.
Figure 5. Nuclear accumulation of endogenous Ptc1 ICD7 fragments in mouse embryonic primary cells. Immunocytochemical analyses
of endogenous Ptc1 ICD7 fragments in mouse embryonic primary cells. (A) Anti-Ptc-ICD7 (1420–1434) antibody staining. (C) Anti-a-tubulin DM1A
antibody as positive control for cytoplasmic immunostaining. (E) Pre-immune serum staining was used as a negative control. 5.5 nM anti-Ptc-ICD7
(1420–1434) primary antibody was absorbed with (I) or without (G) excessive amounts of antigenic peptide. Antigenic peptide concentrations for
competition were 0.6 mM. Hoechst DNA stain, blue (B, D, F, H, J). Scale bar, 20 mm.
doi:10.1371/journal.pone.0018638.g005
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15,24–26,56–58]. Some of oncogenic mutations in Ptc1 gene map
to positions corresponding to the ICD7 region in human cancers
including basal cell carcinoma (BCC) and medulloblastoma
[11,22,24–26,59]. Interestingly, it was recently reported that
susceptibility to skin squamous carcinoma (SCCs) in mice is under
the control of a polymorphism in the ICD7 region of Ptc1 [23].
The involvement of the Ptc-ICD7 region in the development of a
variety of cancers has led to the implementation of different
therapeutic strategies. Challenges for the future will be to
determine how the generation of Ptc-ICD7 fragments is
controlled, and what are the nuclear functions of Ptc-ICD7
fragments. Accordingly, identification of the physiological roles of
nuclear Ptc-ICD7 fragments in the regulation of gene transcription
and modification of tumor suppression should be future prospects.
Materials and Methods
Plasmid construction
The full-length cDNAs of human Ptc1 isoform L (encoding
1447 amino acids) was amplified by RT-PCR from the transcript
of HEK293 cell with SuperScript
TMIII First-Strand Synthesis
System (Invitrogen, CA, USA) and KOD-FX polymerase
(TOYOBO, Japan) with oligonucleotide primers as follow; sense
59-CGACGCGTATGGCCTCGGCTGGTAACGCCG-39, anti-
sense 59-GCGTCGACGTTGGAGCTGCTTCCCCGGGGC-
39. In order to express full-length Ptc1 protein with N-
terminally-T7-tag and C-terminally-FLAG-tag, the PCR products
were digested with MluI and SalI, and inserted into the pCI-
puromycin-T7-FLAG mammalian expression vectors. Note that
pCI-puromycin-T7-FLAG expression vector is a derivative of
pCI-neo mammalian expression vector (Promega, WI, USA) and
contains CMV enhancer/promoter. pCI-puromycin-T7-FLAG
vector was design to include three repeats of a T7-tag at N-
terminus and three repeats of FLAG-tag at C-terminus of its
protein product. Similarly, we also prepare an expression vector
for human full-length Ptc1 with N-terminally-36T7-tag and C-
terminally-26S-tag. A cDNA encoding the Ptc- ICD7 fragment
(C-terminal cytoplasmic domain consisting of residues 1162–1447
of human Ptc1) was PCR amplified with KOD-FX polymerase
and was ligated to pCI-neo mammalian expression vector
(Promega) with C-terminal FLAG-tag. For expression of nematode
Figure 6. Gli1-based luciferase-reporter assay reveals Shh response in Ptc1 transfected cells. (A) Dual-luciferase reporter assay performed
with Gli1 expression vector (Gli1) and a reporter construct consisting of eight copies of the Gli-binding site (8639Gli-BS) or its mutated version
(86m39Gli-BS) as a negative control. Normalization of transfection efficiencies was carried out using Renilla luciferase activities as an internal control.
Relative luciferase activity was monitored in cells stably expressing full-length Ptc1 (Ptc1 FL Stable exp.) and its negative control (Mock exp.) with (+)
or without (2) Shh-N-conditioned media. This medium contains 19 kDa form of Shh-N fragment of Myc-tagged-Shh-N that was processed and
secreted from in HeLa cells expressing full-length Shh. Addition of the Shh-N fragment stimulates transcriptional activity of Gli1 in cells stably
expressing full-length Ptc1. All reporter assay experiments were repeated at least three times, and transfection was done in duplicate. (B) Stably
expressed full-length Ptc1 binds with secreted Shh-N. HeLa cells that were stably expressed N-terminally T7-tagged full-length Ptc1 was exposed to
Myc-Shh-N-conditioned medium. After cells were harvested, full-length Ptc1 was immunoprecipitated with N-terminal T7-tag from solubilized cell
lysates (IP:anti-T7) and precipitates were probed with anti-Myc antibody (IB: anti-Myc). (C) Shh-N stimulates the production of Ptc-ICD7 fragments.
Cells stably expressing full-length Ptc1 (with C-terminal FLAG-tag) were cultured with (+) or without (2) Shh-N-conditioned media. Solubilized cell
lysates were subjected to FLAG-immunoprecipitation and subsequently probed with anti-FLAG antibody. (D) Relative luciferase activity as in (A)
monitored in cells over-expressing Ptc-ICD7 fragment (pCI-Ptc1-ICD7), full-length Ptc1 (pCI-Ptc1 FL), and mock control (pCI-empty).
doi:10.1371/journal.pone.0018638.g006
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protein) [33], corresponding cDNA was subcloned into pCI-neo
expression vector with N-terminal FLAG-tag. Human Shh cDNA
was amplified by RT-PCR from the transcript of HEK293 cell
and the cDNA fragment was subcloned into pCI-neo-66Myc-26S
expression vector. This vector was design to include six repeats of
Myc-tag at N-terminus and two repeats of S-tag at C-terminus of
full-length Shh protein. Sequences of all plasmids were verified
before transfection experiments.
Mammalian cell culture and transfection
HeLa cell [60] was cultured in Dulbecco’s modified Eagle’s
medium (Sigma Chemical Co., St Louis, MO) supplemented with
10% heat-inactivated Calf Serum at 37uC under a 5% CO2
atmosphere. Mouse C3H10T1/2 cells and embryonic primary
cells were cultured as is HeLa cells except for the usage of 10%
heat-inactivated Fetal Calf Serum.
Transfection of the expression vectors to HeLa cells were
performed with HilyMax transfection reagent (Dojindo, Japan)
according to the protocol supplied by the manufacturer. The total
amount of plasmid DNA was adjusted to 1 mg with an empty
vector. At 24 hr after transfection, the cells were harvested and
subjected to immunological analysis unless otherwise noted.
For cycloheximide treatment, pCI-neo expression vector that
encoding C-terminally-FLAG-tagged Ptc-ICD7 was transfected
into HeLa cells. At the time of cDNA transfection, protein
synthesis inhibitor cyclohexamide was added with various
concentrations. We found that 12.5 mg/mL cyclohexamide
treatment completely suppressed protein expression from trans-
fected expression vector. Cells were harvested 24 hr after
transfections for immunological analysis.
To establish stable cell lines that express a moderate level of
human full-length Ptc1 protein, HeLa cells were transfected with
pCI-puromycin-36T7-Ptc1-36FLAG mammalian expression vec-
tors and cultured for one week in the presence of 1.5 mg/mL
puromycin, and colonies that survived were picked up into 24-well
multidish. The cells were culture for another two weeks, and stable
expression of exogenous Ptc1 protein was verified with anti-
FLAG-tag and anti-T7-tag antibodies.
To prepare a Shh-N-conditioned media, an expression vector
that encodes full-length N-terminally-Myc-tagged and C-termi-
nally-S-tagged Shh was transfected into HeLa or HEK293 cells.
At 24 hr after Shh transfection, we confirmed the appearance of
the matured form of Myc-tagged Shh (with a molecular weight of
19 kDa) in the culture media of both HeLa and HEL293 cells. To
remove the non-processed form of Shh (45 kDa form with a C-
terminal S-tag, possibly contaminated from damaged cells), we
pre-cleared the medium with S-agarose beads. To examine the
effect of Shh-N, cells stably expressing human full-length Ptc1 with
an N-terminal T7-tag and a C-terminal FLAG-tag were exposed
to Shh-N-conditioned media for 4 hr.
Immunological analysis
The anti-Ptc1 ICD7 C-terminal antibody (designated anti-Ptc-
ICD7 (1420–1434) antibody) was prepared for this study as
follows. The antigenic peptide used in this study corresponds to
human Ptc1 C-terminal amino acids sequence 1420–1434
(CERRDSKVEVIELQD) that is a region specific to Ptc1 among
the predicted human protein sequences from the genome
database. Immunization to the rabbit with 0.3 mg antigenic
peptide was performed for six times at two-week intervals by
Operon Biotechnologies (Tokyo, Japan). The antibody was
successively purified with Protein A-Sepharose and antigenic
peptide affinity chromatography. Antigenic sequence is completely
conserved between human and mouse, and we confirmed that the
antibody thus obtained can efficiently recognize both of human
and mouse Ptc1.
For immunoprecipitation analysis, cells were washed with ice-
cold phosphate-buffered saline and lysed with immunoprecipita-
tion (IP) buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 1% NP-40, 10 mM N-ethylmaleimide,
100 mM MG132 and Complete
TM protease inhibitor cocktail (GE
healthcare). The lysate was sonicated for one second and
centrifuged at 20,0006 g for 10 min at 4uC, and the resulting
supernatant was incubated with 3 mL of anti-Flag M2-agarose
beads (Sigma) for 2 hr at 4uC. After the beads had been washed
five times with the IP buffer, the precipitated immunocomplexes
were subjected to SDS-PAGE.
For Western blot analysis, the whole cell lysate and immuno-
precipitates were separated by SDS-PAGE and transferred onto
PVDF membranes (GE Healthcare). The membranes were
probed with specific antibodies as indicated and then incubated
with horseradish peroxidase-conjugated antibody against mouse
and rabbit immunoglobulin (GE Healthcare), followed by
detection with ECL Western blotting detection reagents (GE
healthcare).
The following antibodies were used for immunological analyses
in this study: anti-FLAG polyclonal (Sigma), anti-FLAG M2
monoclonal (Sigma), anti-T7 tag
R monoclonal (Novagen), anti-
Ptc-ICD7 C-terminal (1420–1434) (prepared in this study), anti-
human Ptc1 SSD (500–600) (Abcam, Cat. No. ab39266), anti-
human Ptc1 ICD7 peptide (1271-HPESRHHPPSNPRQQ-1285)
antibody (Abcam, Cat. No. 51983), anti-TRA-2 ICD7 [33], anti-
tubulin (ICN), anti-BIP (BD Bioscience), anti-Histone H2B (Santa
Cruz), Alexa Fluor
R488 anti-rabbit IgG (Invitrogen), Alexa
Fluor
R488 anti-mouse IgG (Invitrogen), Alexa Fluor
R568 anti-
mouse IgG (Invitrogen), HRP-conjugated anti-rabbit IgG (GE
healthcare), and HRP-conjugated anti-mouse IgG (GE health-
care).
Microscopic observations
For immunocytochemical observations of cultured cells, cells
were grown on micro coverglass (Matsunami, Japan), fixed by
incubating in 4% paraformaldehyde, and were then permeabilized
with 0.1% Triton X-100. Fixed cells were blocked with 3% calf
serum in PBS and reacted with a series of primary antibodies at
room temperature for one hour. For examples, affinity-purified
anti-Ptc-ICD7 C-terminal (1420–1434) antibody was diluted to a
concentration of 5.5 nM (about 0.8 mg/mL) before incubation.
For peptide competition experiments, an antigenic peptide was
used at concentrations of 1.2 mM or 0.6 mM. Anti-T7-tag and
anti-FLAG-tag antibodies were used at 15 nM. Alexa
TM 488-
conjugated anti-rabbit IgG antibody and Alexa
TM 594-conjugated
anti-mouse IgG antibody (Molecular Probes) were used as
secondary antibodies at 1:800 dilution. To observe the nucleus,
cells were treated with 2.5 mg/ml Hoechst 33342 or DAPI for
15 minutes at 25uC and then washed another three times in PBS-
T. Immunofluorescent images were obtained with BIOREVO
BZ9000 fluorescence microscope (Keyence, Japan) and an
LSM510 invert confocal microscopy system (Carl Zeiss, Ger-
many).
Subcellular fractionation
Subcellular fractionation of HeLa cells was performed as
follows. (Step I) stably transfected cells were harvested and
suspended in 200 mL of Solution buffer (20 mM HEPES,
pH 7.4, 1 mM EDTA and 0.25 M sucrose) by 15 strokes of a
27G needle. After centrifugation at 1,0006g for 10 min, the
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fractions. (Step II) the pellets were re-suspended in 400 mLo f
Fraction buffer (20 mM HEPES, pH 7.4, 3 mM MgCl2 and
10 mM NaCl), incubated for 10 min on ice, added NP-40 to final
concentration of 0.5% and centrifugation at 10,0006g for 20 sec
after voltex mixing. Step II was repeated twice and resulting pellets
were collected as nuclear fractions.
For C3H10T1/2 cell fractionation, cells were suspended in
200 mL of Low Osmotic buffer (10 mM HEPES, pH 7.9, 10 mM
KCl,1.5 mMMgCl2,10 mMDTTand1.5%NP-40)withpipetting
10 times. After centrifugation at 7506g for 10 min, the supernatants
(post-nuclear fraction) were collected as the cytoplasmic fraction.
The pellets were re-suspended in 500 mL of Low Osmotic buffer
with pipetting 10 times. After centrifugation at 7506gf o r1 0m i n ,
the pellets were suspended in 500 mLo fc o l dP B Sa n dc e n t r i f u g e da t
7506g for 10 min. After repeating PBS re-suspension twice,
resulting pellets were collected as the nuclear fraction. The nuclear
fraction was sonicated with SDS sample buffer and subjected to
electrophoresis analysis with the cytoplasmic fraction.
Luciferase assay
The reporter plasmids 8639Gli-BSd51LucII and 86m39Gli-
BSd51LucII were constructed by placing eight copies of a Gli-
binding site element present in the mouse HNF-3b enhancer or a
mutated version of it [41]. After cDNA transfection, HeLa cells
were harvested and transcriptional activity of Gli1 was monitored
by the Dual-Luciferase
R Reporter Assay System (Promega)
according to the protocol supplied by the manufacturer.
Normalization of transfection efficiencies was carried out using
Renilla luciferase activities. All reporter assay experiments were
repeated at least three times, and transfection was done in
triplicate. Reporter plasmids 8639Gli-BSd51LucII and 86m39Gli-
BSd51LucII as well as Gli1 expression vector (pcDNA3.1-HisB-
Gli1) were generous gifts from Dr. H. Sasaki (Kumamoto Univ.,
Japan).
Supporting Information
Figure S1 Comparison of nematode TRA-2 and human
Ptc1. (A, B) Hydropathy analyses of human Ptc1 and nematode
TRA-2 sequences suggest that both proteins are composed of 12
membrane-spanning helices like members of transporter super-
family. Both Ptc1 and TRA-2 proteins appear to be topologically
duplicated as it is composed of tandemly-repeated motif of six
hydrophobic domains. Ptc1 and TRA-2 share similar structure,
implying that they originate from common ancestor. (C) Amino
acid sequence alignment of seventh intracellular domain of human
Ptc1 (Ptc-ICD7) and C. elegans TRA-2 (TRA-2 ICD7). Identical
amino acids are boxed by red, and related amino acids are boxed
by orange. Antigenic sequence of anti-Ptc-ICD7 (1420–1434)
antibody was indicated with underline. Amino acid number was
derived from human Ptc1 isoform L.
(EPS)
Figure S2 TRA-2 ICD7 is localized in the nucleus. (A)
Nuclear localization of endogenous TRA-2 ICD7 fragment in
wild-type young adult hermaphrodite nematodes. Nuclei of
intestinal cells were specifically stained with an anti-TRA-2
ICD7 antibody, while the nuclei were scarcely stained with
preimmune IgG. Note that each photograph were taken with
identical exposure time. Immuno-staining in green, Hoechst DNA
stain in blue. Scale bar, 100 mm. (B) Flag-tagged TRA-2 ICD7
protein (fragments of amino acids 1135–1475 of TRA-2) was
subcloned into pCI-neo expression vector and the protein
fragment was transiently expressed in HeLa cells. Forced
expression of TRA-2 ICD7 fragment results in accumulation in
the nucleus of HeLa cells. TRA-2 ICD7-positive nuclei were
indicated by arrowheads. Scale bar, 20 mm.
(EPS)
Figure S3 Comparison of expression level of Ptc1 in
HeLa cells. Ectopically-expressed Ptc1 proteins were probed
with anti-Ptc-ICD7 antibody. Note that production of full-length
Ptc1 by ‘‘transient’’ expression results in much larger amounts of
accumulation compared to that of ‘‘stable’’ expression.
(EPS)
Figure S4 Ectopically-expressed Ptc1 protein detected
with anti-Ptc-ICD7 (1420–1434) antibody in C3H10T1/2
cells. Human full-length Ptc1 cDNA in an expression vector was
transiently transfected into C3H10T1/2 cells, and whole cell
lysates were immunoblotted with anti-Ptc-ICD7 (1420–1434)
antibody. Mock transfected cells were used as a negative control.
(EPS)
Figure S5 Effects of protease inhibitors on the appear-
ance of Ptc1 C-terminal fragments. HeLa cells stably
expressing full-length Ptc1 were treated with a series of protease
inhibitors at 20 mM for 13 hr. C-terminal ICD7 fragments were
detected by anti-FLAG antibody, while the full-length form of Ptc1
(Ptc1 FL) was detected with N-terminal T7-tag. Anti-actin
immunoblots were used as loading control.
(EPS)
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